Literature DB >> 18415078

Comment on "Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008" by Dellinger et al.

A M E Spoelstra-de Man, A R J Girbes.   

Abstract

Entities:  

Mesh:

Year:  2008        PMID: 18415078      PMCID: PMC2480487          DOI: 10.1007/s00134-008-1089-5

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
Sir: We read with interest the recent revision of the Surviving Sepsis Campaign (SSC) guidelines by Dellinger et al. [1]. The use of the GRADE system to classify the strength of the recommendations has certainly improved the guidelines. However, we regret that not all guidelines were adjusted according to the current literature. First of all, the absence of a recommendation regarding selective digestive tract decontamination (SDD) is striking. The guidelines group was evenly split, with equal numbers weakly in favor and against recommending the use of SDD. This is remarkable, since SDD is one of the best ever evaluated therapies in intensive care medicine, with more than 50 randomized controlled trials and 10 meta-analyses showing that SDD reduces pneumonia by 65% and mortality by 22% [2]. The authors gave several reasons why they chose not to recommend SDD in their guidelines. They argue that no studies regarding SDD specifically focused on septic patients. However, several other guidelines based on general ICU populations (i.e., stress ulcer prophylaxis, deep vein thrombosis prophylaxis, glucose control and bicarbonate therapy) received strong recommendations. Furthermore, the authors state that studies comparing SDD with non-antimicrobial interventions, such as ventilator bundles, are needed. Are they seriously suggesting that until these studies have been performed a therapy with proven high efficiency should be withheld from patients with severe sepsis? It seems that no scientific arguments, no study whatsoever could change the apparently biased authors. The main argument against the use of SDD is the persistent concern regarding emergence of antimicrobial resistance in critically ill patients. Antimicrobial resistance was not a clinical problem in 10 SDD studies monitoring resistance for 2–9 years [3-11]. SDD even seemed to reduce the resistance of aerobic Gram-negative bacilli, the target microorganisms of SDD [12, 13], possibly because the addition of enteral to parenteral antimicrobials prevents spontaneous mutation of target bacteria and eradicates mutants. In their “rationale” the authors are especially concerned about emergence of resistant Gram-positive infections. The SDD prophylaxis is not active against vancomycin-resistant enterococci (VRE) and methicillin-resistant S. aureus (MRSA) and may promote gut overgrowth of these intrinsically resistant bacteria. Therefore, in ICUs with endemic MRSA enteral vancomycin is required as a component of SDD. VRE did not emerge in any of the studies using enteral vancomycin, and there is no evidence that SDD promotes infection due to Gram-positive bacteria [14-19]. On the contrary, the continued use of only systemic antibiotics may lead to a further rise in drug-resistant Gram-positive bacteria. We propose, therefore, that the authors of the SSC guidelines use the available literature instead of their bias. Secondly, the strong recommendation in favor of the use of stress ulcer prophylaxis is not, in our view, in line with currently available evidence. This recommendation is, like that in the guidelines of 2004, still mainly based on ancient studies performed in the 1980s [20-23], a meta-analysis from 1991 [24], and a large trial in 1998 [25] without a control arm. However, the most recent meta-analysis [26] shows no reduction of clinical important bleeding – but is somehow completely ignored. Whether the results of these older trials are applicable nowadays is questionable, since the incidence of stress ulcer-related bleeding has significantly decreased over recent decades due to improved ICU treatment [27, 28]. This definitely affects the balance between the benefit of prevention of gastro-intestinal bleeding and the increased risk of ventilator-associated pneumonia due to higher stomach pH [29]. Several recent trials show comparable rates of bleeding and endoscopic evidence of stress-related injury between treatment and placebo groups [30-33]. These results are pathophysiologically plausible, since stress ulcers are caused not by increased secretion of gastric acid, but by splanchnic hypoperfusion. Unfortunately, many recent trials only compare H2 blockers with proton pump inhibitors, without a placebo group. Altogether, according to the most recent meta-analysis and the more recent trials, a strong recommendation not to use stress ulcer prophylaxis would be more appropriate. Thirdly, we disagree with the strength of the recommendation to reduce blood glucose levels in patients with severe sepsis. On the current evidence, this should be at most a weak recommendation. The beneficial effect of intensive insulin therapy has been demonstrated only in surgical patients, not in septic patients [34-36]. The benefit versus harm balance of intensive insulin therapy may be quite different for patients with severe sepsis than for the investigated surgical patients. It is not unreasonable to assume that septic patients may be more at risk for hypoglycemia, because sepsis may be associated with a deficiency of counterregulatory hormones. In the study of medical patients by van den Berghe [36], as well as the VISEP study [35] and the Glucontrol study [34], the risk of hypoglycemia was substantially increased, and hypoglycemia was an independent risk factor for mortality. None of these studies followed up the patients with hypoglycemia for neurocognitive impairment. Furthermore, the target glucose level of <150 mg/dl recommended in the guidelines is based solely on expert opinion and is not supported by data from any trial. Therefore, the beneficial effect, the harmlessness, and the target glucose level of intensive insulin therapy remain to be demonstrated in septic patients. In conclusion, the revised SSC guidelines have certainly been improved by the use of the GRADE system to classify the strength of the recommendations. However, a strong recommendation in favor of the use of SDD should have been implemented. The strong recommendations in favor of stress ulcer prophylaxis and glucose control are not in line with current evidence.
  33 in total

1.  Prevention of ventilator-associated pneumonia by oral decontamination: a prospective, randomized, double-blind, placebo-controlled study.

Authors:  D C Bergmans; M J Bonten; C A Gaillard; J C Paling; S van der Geest; F H van Tiel; A J Beysens; P W de Leeuw; E E Stobberingh
Journal:  Am J Respir Crit Care Med       Date:  2001-08-01       Impact factor: 21.405

2.  Intensive insulin therapy in the medical ICU.

Authors:  Greet Van den Berghe; Alexander Wilmer; Greet Hermans; Wouter Meersseman; Pieter J Wouters; Ilse Milants; Eric Van Wijngaerden; Herman Bobbaers; Roger Bouillon
Journal:  N Engl J Med       Date:  2006-02-02       Impact factor: 91.245

3.  An observational study of upper gastrointestinal bleeding in intensive care units: is Helicobacter pylori the culprit?

Authors:  Eric Maury; Jacques Tankovic; Anne Ebel; Georges Offenstadt
Journal:  Crit Care Med       Date:  2005-07       Impact factor: 7.598

4.  A before-after study of multi-resistance and cost of selective decontamination of the digestive tract.

Authors:  P H J van der Voort; E N van Roon; G A Kampinga; E C Boerma; R Th Gerritsen; P H M Egbers; M A Kuiper
Journal:  Infection       Date:  2004-10       Impact factor: 3.553

5.  Selective decontamination of the digestive tract in neurosurgical intensive care unit patients: a double-blind, randomized, placebo-controlled study.

Authors:  A M Korinek; M J Laisne; M H Nicolas; L Raskine; V Deroin; M J Sanson-Lepors
Journal:  Crit Care Med       Date:  1993-10       Impact factor: 7.598

6.  Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial.

Authors:  Ilona Kantorova; Petr Svoboda; Peter Scheer; Jaroslav Doubek; Dagmar Rehorkova; Hana Bosakova; Jiri Ochmann
Journal:  Hepatogastroenterology       Date:  2004 May-Jun

7.  Long-term effects of selective decontamination on antimicrobial resistance.

Authors:  J M Hammond; P D Potgieter
Journal:  Crit Care Med       Date:  1995-04       Impact factor: 7.598

8.  The virtual absence of stress-ulceration related bleeding in ICU patients receiving prolonged mechanical ventilation without any prophylaxis. A prospective cohort study.

Authors:  D F Zandstra; C P Stoutenbeek
Journal:  Intensive Care Med       Date:  1994-05       Impact factor: 17.440

9.  Stress ulcer prophylaxis in the critically ill: a meta-analysis.

Authors:  D J Cook; L G Witt; R J Cook; G H Guyatt
Journal:  Am J Med       Date:  1991-11       Impact factor: 4.965

10.  Intestinal decontamination for control of nosocomial multiresistant gram-negative bacilli. Study of an outbreak in an intensive care unit.

Authors:  C Brun-Buisson; P Legrand; A Rauss; C Richard; F Montravers; M Besbes; J L Meakins; C J Soussy; F Lemaire
Journal:  Ann Intern Med       Date:  1989-06-01       Impact factor: 25.391

View more
  8 in total

Review 1.  Biomarkers of Sepsis-Induced Acute Kidney Injury.

Authors:  Kaifei Wang; Sheling Xie; Kun Xiao; Peng Yan; Wanxue He; Lixin Xie
Journal:  Biomed Res Int       Date:  2018-04-24       Impact factor: 3.411

2.  Association Between Early Administration of Norepinephrine in Septic Shock and Survival.

Authors:  Mohammed S Alshahrani; Rawan Alatigue
Journal:  Open Access Emerg Med       Date:  2021-03-31

3.  Heparin-Binding Protein Aggravates Acute Lung Injury in Septic Rats by Promoting Macrophage M1 Polarization and NF-κB Signaling Pathway Activation.

Authors:  Ying Zhang; Wenqiao Sun; Licheng Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-10-03       Impact factor: 2.650

4.  Epidemiology of acute kidney injury in the intensive care unit.

Authors:  James Case; Supriya Khan; Raeesa Khalid; Akram Khan
Journal:  Crit Care Res Pract       Date:  2013-03-21

5.  The safety of beta-blocker use in chronic obstructive pulmonary disease patients with respiratory failure in the intensive care unit.

Authors:  Feyza Kargin; Huriye Berk Takir; Cuneyt Salturk; Nezihe Ciftaslan Goksenoglu; Can Yucel Karabay; Ozlem Yazicioglu Mocin; Nalan Adiguzel; Gokay Gungor; Merih Kalamanoglu Balci; Murat Yalcinsoy; Ramazan Kargin; Zuhal Karakurt
Journal:  Multidiscip Respir Med       Date:  2014-02-04

Review 6.  Therapeutic applications of carbon monoxide.

Authors:  Melissa Knauert; Sandeep Vangala; Maria Haslip; Patty J Lee
Journal:  Oxid Med Cell Longev       Date:  2013-12-04       Impact factor: 6.543

7.  Clinical features and factors associated with severity and fatality among patients with severe fever with thrombocytopenia syndrome Bunyavirus infection in Northeast China.

Authors:  Baocheng Deng; Bo Zhou; Shujun Zhang; Ying Zhu; Leqiang Han; Yingzhi Geng; Zhenan Jin; Hongbo Liu; Donglei Wang; Yitong Zhao; Ying Wen; Wei Cui; Ying Zhou; Qiuhong Gu; Cuiming Sun; Xu Lu; Wen Wang; Yu Wang; Chengbo Li; Yanli Wang; Wenqing Yao; Pei Liu
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

8.  Management and outcomes of patients presenting with sepsis and septic shock to the emergency department during nursing handover: a retrospective cohort study.

Authors:  Sami Alsolamy; Atheer Al-Sabhan; Najla Alassim; Musharaf Sadat; Eman Al Qasim; Hani Tamim; Yaseen M Arabi
Journal:  BMC Emerg Med       Date:  2018-01-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.